SIRT1 plays key role in chronic myeloid leukemia to aid persistence of leukemic stem cells

June 10, 2019

BIRMINGHAM, Ala. - Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure.

As a result, the majority of patients with chronic myeloid leukemia, or CML, require indefinite inhibitor treatment to prevent disease recurrence. They also face risks of noncompliance, toxicity and financial burden. Development of effective therapeutic strategies to improve patient outcomes for CML and related cancers depends on identifying the key mechanisms that contribute to the persistence of these leukemic stem cells.

In a study published in the Journal of Clinical Investigation, Ajay Abraham, Ph.D., Shaowei Qiu, M.D., Ravi Bhatia, M.D., and colleagues at the University of Alabama at Birmingham show how the stress-responsive protein SIRT1 plays important roles in maintaining the regenerative potential of CML leukemic stem cells and promoting leukemia development in CML.

"Our studies provide a conceptual advance and new biological insights regarding the activity of SIRT1 and its role in CML leukemic stem cells," said senior author Bhatia. At UAB, Bhatia is a professor of medicine, director of the Division of Hematology and Oncology, and interim director of the O'Neal Comprehensive Cancer Center at UAB.

In 2012, Bhatia and colleagues reported that SIRT1 was overexpressed in CML leukemic stem cells compared to normal hematopoietic stem cells, and this overexpression contributed to CML leukemic stem cell maintenance and resistance to tyrosine kinase inhibitors. However, the underlying mechanisms were not known.

To study those mechanisms, the UAB researchers used a CML mouse model that also has a genetic deletion of SIRT1. This allowed them to compare wild-type leukemic stem cells with SIRT1-deletion leukemic stem cells.

Study details

They found that SIRT1 plays an important role to enhance oxidative phosphorylation by the mitochondria in leukemic stem cells. Furthermore, the researchers found that this increased mitochondrial metabolism in leukemic stem cells did not depend on activity of the mutated kinase that transforms the normally quiescent hematopoietic stem cells into leukemic stem cells.

Mitochondria are the powerhouses of the cell, supplying nearly all the energy a cell normally needs. Oxidative phosphorylation uses oxygen in producing energy; non-leukemic hematopoietic stem cells -- the non-cancerous blood-forming cells of the body, from healthy mice or humans, produce energy by an alternative metabolism called glycolysis.

Treatment with tyrosine kinase inhibitors is known to suppress leukemic hematopoiesis. When SIRT1-deleted mice were treated with tyrosine kinase inhibitors, the UAB researchers found an even greater suppression of leukemic hematopoiesis.

The SIRT1 knock-out also impaired development of CML in the mouse model. Compared with the CML mice without SIRT1 knock-out, the researchers saw significant delays in developing increased numbers of leukocytes and neutrophils, and delayed enlargement of the spleen and time of death. The deletion also reversed redistribution of CML stem cells from the bone marrow to the spleen.

SIRT1 is a deacetylase enzyme, known to deacetylate and activate the transcriptional co-activator PGC-1-alpha. This enhances mitochondrial DNA replication and gene expression, and it promotes mitochondrial activity. Bhatia and colleagues showed that PGC-1-alpha inhibitors were able to significantly reduce mitochondrial oxygen consumption, a sign of oxidative phosphorylation. Thus, the inhibitors acted similarly to the SIRT1 deletion. This finding supports an important role for PGC-1-alpha in the regulation of mitochondrial metabolism in CML stem and progenitor cells.

The researchers also found that a chemical inhibitor of SIRT1 was able to reduce oxidative phosphorylation in both mouse and human CML leukemic stem cells.

Interestingly, the SIRT1 deletion in normal, non-leukemic blood-forming stem cells did not inhibit steady-state normal hematopoiesis in the mouse model. Bhatia noted that development of effective approaches to target the persistent CML leukemic stem cells that resist tyrosine kinase-inhibitor treatment -- while not causing toxicity to normal hematopoietic stem cells -- has been a challenge.

Bhatia says the impact of this study extends to other hematological malignancies, including acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms.

"Our research reveals new knowledge and concepts regarding the role of SIRT1 in metabolic regulation of hematopoietic stem cell and leukemic stem cell maintenance, growth and resistance," Bhatia said. "This raises the possibility of developing improved strategies to target kinase-independent metabolic alterations."
-end-
Abraham and Qiu are co-first authors on the Journal of Clinical Investigation study, "SIRT1 regulates metabolism and leukemogenic potential in CML stem cells." Abraham was a postdoctoral fellow in the Division of Hematology and Oncology, UAB Department of Medicine. Qui is a visiting instructor in that division. Besides Abraham, Qiu and Bhatia, co-authors are Balu K. Chacko and Victor M. Darley-Usmar, UAB Department of Pathology, who provided expertise in metabolic analyses; and Hui Li, Andrew Paterson, Jianbo He, Puneet Agarwal, Mansi Shah and Robert Welner, Division of Hematology and Oncology, UAB Department of Medicine.

Support came from National Institutes of Health grant CA95684.

At UAB, Darley-Usmar holds the Endowed Professorship in Mitochondrial Medicine and Pathology.

University of Alabama at Birmingham

Related Chronic Myeloid Leukemia Articles from Brightsurf:

Young survivors of acute myeloid leukemia have long-term complications from treatment
Adolescent and young adult (AYA) patients treated for acute myeloid leukemia (AML) have a high risk of developing several long-term health complications after treatment, a study led by UC Davis Comprehensive Cancer Center researchers has found.

Combination therapy improves survival outcomes for patients with acute myeloid leukemia
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.

ASH releases new clinical practice guidelines on acute myeloid leukemia in older adults
Today, ASH published new guidelines to help older adults with acute myeloid leukemia (AML) and their health care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for blood transfusions for those in hospice care.

Huntsman Cancer Institute illuminates potential new treatment in acute myeloid leukemia
In a study published in the journal Leukemia, lead author Ami Patel, MD, Huntsman Cancer Institute researcher and assistant professor in the Division of Hematology and Hematologic Malignancies at the University of Utah, showed that factors produced by bone marrow support cells allowed leukemia cells to survive treatment with quizartinib, a type of TKI.

A new nanoconjugate blocks acute myeloid leukemia tumor cells without harming healthy ones
The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments.

Oncotarget: RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation
The cover for issue 25 of Oncotarget features Figure 8, 'BI-D1870 in combination with vincristine increase metaphase arrest and apoptosis synergistically,' by Chae, et al.

Call for caution for using a CAR-T immunotherapy against acute myeloid leukemia
Researchers from the Josep Carreras Leukaemia Research Institute prove that the preclinical implementation of Acute Myeloid Leukaemia immunotherapy, based on CD123-redirected CAR T-cells, affects hematopoiesis, blood cells production, and reconstitution.

For acute myeloid leukemia, genetic testing is often worth the wait
New tailored therapies offer exciting prospects for treating acute myeloid leukemia (AML), but taking advantage of them may require waiting a week or more for genetic testing before starting treatment, posing a dilemma for doctors and patients facing this deadly and often fast-moving disease.

Discovery in human acute myeloid leukemia could provide novel pathway to new treatments
Researchers at Mount Sinai have discovered that human acute myeloid leukemia (AML) stem cells are dependent on a transcription factor known as RUNX1, potentially providing a new therapeutic target to achieve lasting remissions or even cures for a disease in which medical advances have been limited.

Research revises classification of acute myeloid leukemia & myelodysplastic syndrome
Findings presented as a late-breaking abstract at the American Society of Hematology annual meeting by St.

Read More: Chronic Myeloid Leukemia News and Chronic Myeloid Leukemia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.